Ocular Therapeutix

OCUL

Market cap $1.97B

BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Amy Ricca, the Company's new SVP, Head of HR. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.37 per share a year ago.

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027 HELIOS-3 Phase 3 trial in diabetic retinopathy ongoing Ocular to host Investor Day on Wednesday, June 17, 2026, in New York City, including key program and regulatory updates Cash balance of $666.7 million as of March 31, 2026, with expected runway into 2028 BEDFORD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial  Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R have an opportunity to enroll in the SOL-X trial for an additional three years SOL-X is designed to build on AXPAXLI's successful SOL-1 Phase 3 trial by exploring the potential to improve long-term visual outcomes with a dramatically reduced treatment burden BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been enrolled in the SOL-X long-term extension trial for AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).

BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026.

Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026

New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control